FDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 Diabetes

The US Food and Drug Administration (FDA) recently approved Novo Nordisk’s oral semaglutide, marketed as Rybelsus, to reduce the risk of major adverse cardiac events in adults with type 2 diabetes who are at high risk of these conditions.

Authors

Publication Details

Journal
JAMA
Published
2025-11-07
DOI
https://doi.org/10.1001/jama.2025.19724
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

FDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 Diabetes

Saumya Pant
JAMA
Diabetes Treatment and Management
article

FDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 Diabetes

Saumya Pant
article en

Abstract

The US Food and Drug Administration (FDA) recently approved Novo Nordisk’s oral semaglutide, marketed as Rybelsus, to reduce the risk of major adverse cardiac events in adults with type 2 diabetes who are at high risk of these conditions.

JAMAVol. 334(22)
Openalex Percentile: Top 55%
Diabetes Treatment and Management
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

FDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 Diabetes — Saumya Pant · JAMA (2025) | TGRS Research Map | TGRS